Nuclear transport as a target for cell growth - PubMed (original) (raw)
Review
Nuclear transport as a target for cell growth
Tweeny R Kau et al. Drug Discov Today. 2003.
Abstract
The function of many key proteins and transcription factors involved in cell growth can be regulated by their cellular localization. Such proteins include the tumor suppressor p53 and the nuclear factor kappaB. Although the idea of trapping such proteins in either the nucleus or cytoplasm has been introduced as a potential therapeutic target, only two nuclear transport inhibitors have been reported. Here, we explore the roles of small-molecule inhibitors that cause target proteins to sequester in either the nucleus or cytoplasm. Methods of artificially targeting proteins to the nucleus or cytoplasm using peptide aptamer technology are also discussed.
Comment in
- Nuclear transport as a target for cancer therapies.
Henderson B. Henderson B. Drug Discov Today. 2003 Mar 15;8(6):249. doi: 10.1016/s1359-6446(03)02628-x. Drug Discov Today. 2003. PMID: 12623236 No abstract available.
Similar articles
- Real-time visualization of ZBP1 association with beta-actin mRNA during transcription and localization.
Oleynikov Y, Singer RH. Oleynikov Y, et al. Curr Biol. 2003 Feb 4;13(3):199-207. doi: 10.1016/s0960-9822(03)00044-7. Curr Biol. 2003. PMID: 12573215 Free PMC article. - Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs.
Yashiroda Y, Yoshida M. Yashiroda Y, et al. Curr Med Chem. 2003 May;10(9):741-8. doi: 10.2174/0929867033457791. Curr Med Chem. 2003. PMID: 12678777 Review. - Clinical translation of nuclear export inhibitors in cancer.
Senapedis WT, Baloglu E, Landesman Y. Senapedis WT, et al. Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19. Semin Cancer Biol. 2014. PMID: 24755012 Review.
Cited by
- Aggregation-Induced Emission Luminogens for Enhanced Photodynamic Therapy: From Organelle Targeting to Tumor Targeting.
Zhou J, Qi F, Chen Y, Zhang S, Zheng X, He W, Guo Z. Zhou J, et al. Biosensors (Basel). 2022 Nov 16;12(11):1027. doi: 10.3390/bios12111027. Biosensors (Basel). 2022. PMID: 36421144 Free PMC article. Review. - Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB. Yang J, et al. PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014. PLoS One. 2014. PMID: 25057921 Free PMC article. - The CRM1 nuclear export receptor controls pathological cardiac gene expression.
Harrison BC, Roberts CR, Hood DB, Sweeney M, Gould JM, Bush EW, McKinsey TA. Harrison BC, et al. Mol Cell Biol. 2004 Dec;24(24):10636-49. doi: 10.1128/MCB.24.24.10636-10649.2004. Mol Cell Biol. 2004. PMID: 15572669 Free PMC article. - Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M. Yuen HF, et al. Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16. Clin Cancer Res. 2012. PMID: 22090358 Free PMC article. - Identification of essential sequences for cellular localization in BRMS1 metastasis suppressor.
Rivera J, Megías D, Navas C, Bravo J. Rivera J, et al. PLoS One. 2009 Jul 30;4(7):e6433. doi: 10.1371/journal.pone.0006433. PLoS One. 2009. PMID: 19649328 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous